Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECCO 2017 | Managing toxicity from immunotherapy

Martin Gore • 27 Jan 2017
ECCO 2017

Martin Gore, PhD, FRCP, CBE from the Royal Marsden NHS Foundation, London, UK discusses the risks from immunotherapy at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. Toxicity from immunotherapy is a significant consideration as they can lead to complex consequences, in particular, the combination of immune checkpoint inhibitors and CAR T-cells. Toxicity management is therefore something that needs to become more organised and managed.

More from Martin Gore

The resurgence of immunotherapy in the treatment of cancer
2:06
The resurgence of immunotherapy in the treatment of cancer
Martin Gore • 27 Jan 2017
The success of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
2:49
The success of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
Martin Gore • 27 Jan 2017
The debate on MDT meetings
0:58
The debate on MDT meetings
Martin Gore • 10 Nov 2016
The changing function of MDT meetings
3:37
The changing function of MDT meetings
Martin Gore • 10 Nov 2016

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals